1.Clinical Characteristics and Prognosis of Multiple Myeloma Patients with Myelofibrosis.
Lu CHENG ; Li-Min SONG ; Ru XUE ; Yan-Ping MA
Journal of Experimental Hematology 2022;30(1):141-145
OBJECTIVE:
To investigate the clinical characteristics and prognosis of multiple myeloma patients with myelofibrosis.
METHODS:
The clinical data of 263 patients with multiple myeloma (including 92 patients with myelofibrosis) treated in the department of hematology of our hospital from January 1, 2016 to June 31, 2020 were collected and retrospectively analyzed, the patients were divided into combined group and uncombined group. The MM stage, MM type, genetic characteristics and therapeutic effect of the patients in combined group and uncombined group were observed, and the relationship between the curative effect and the degree of myelofibrosis change of the patients in combined group was analyzed.
RESULTS:
There was no statistically difference in the MM staging and classification between multiple myeloma patients with or without myelofibrosis (P>0.05). The positive rate of FISH results of the patients in combined group was significantly higher than those in uncombined group, and was significantly correlated to 1q21 amplification, D13S319 deletion, and IgH breakage (P<0.05). After treatment, the effective rate of the patients in uncombined group was significantly higher than those in combined group, and the degree of fibrosis in the effective patients in combined group was significantly reduced.
CONCLUSION
The survival rate of the patients with multiple myeloma complicated with myelofibrosis is shorter than that of the patients without myelofibrosis, and the overall prognosis is poor.
Chromosome Aberrations
;
Humans
;
Multiple Myeloma/complications*
;
Primary Myelofibrosis/complications*
;
Prognosis
;
Retrospective Studies
3.Chronic Idiopathic Myelofibrosis Presenting as Cauda Equina Compression due to Extramedullary Hematopoiesis: A Case Report.
Duck Ho GOH ; Sun Ho LEE ; Dae Chul CHO ; Seong Hyun PARK ; Jeong Hyun HWANG ; Joo Kyung SUNG
Journal of Korean Medical Science 2007;22(6):1090-1093
Extramedullary hematopoiesis (EMH) is occasionally reported in idiopathic myelofibrosis and is generally found in the liver, spleen, and lymph nodes several years after diagnosis. Myelofibrosis presenting as spinal cord compression, resulting from EMH tissue is very rare. A 39-yr-old man presented with back pain, subjective weakness and numbness in both legs. Sagittal magnetic resonance imaging showed multiple anterior epidural mass extending from L4 to S1 with compression of cauda equina and nerve root. The patient underwent gross total removal of the mass via L4, 5, and S1 laminectomy. Histological analysis showed islands of myelopoietic cells surrounded by fatty tissue, consistent with EMH, and bone marrow biopsy performed after surgery revealed hypercellular marrow and megakaryocytic hyperplasia and focal fibrosis. The final diagnosis was chronic idiopathic myelofibrosis leading to EMH in the lumbar spinal canal. Since there were no abnormal hematological findings except mild myelofibrosis, additional treatment such as radiothepary was not administered postoperatively for fear of radiotoxicity. On 6 month follow- up examination, the patient remained clinically stable without recurrence. This is the first case of chronic idiopathic myelofibrosis due to EMH tissue in the lumbar spinal canal in Korea.
Adult
;
*Cauda Equina
;
Chronic Disease
;
*Hematopoiesis, Extramedullary
;
Humans
;
Male
;
Primary Myelofibrosis/*complications
;
Spinal Cord Compression/*etiology
4.Recent Research Advance to Differentiate Portal Hypertension Associated with Primary Myelofibrosis and Cirrhosis --Review.
Rui LI ; Hua-Sheng LIU ; Ying CHEN
Journal of Experimental Hematology 2023;31(2):598-601
Primary myelofibrosis (PMF) is easily confused with cirrhosis, due to its main clinical manifestations of splenomegaly and the blood cytopenia. This review focuses on clinical studies to identify primary myelofibrosis and cirrhosis related portal hypertension, to analyze the differences between the two diseases, in order to distinguish PMF and cirrhosis from the pathogenesis, clinical manifestations, laboratory examinations and treatment principles, and simultaneously improve clinicians' understanding of PMF, which is a reference for exploring the early screening or diagnostic indicators of PMF, also provides a clinical basis for the application of new targeted drugs such as ruxolitinib.
Humans
;
Primary Myelofibrosis/drug therapy*
;
Hypertension, Portal/complications*
;
Liver Cirrhosis/pathology*
;
Splenomegaly/pathology*
;
Anemia
5.The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients.
Junqing XU ; Zefeng XU ; Jingya WANG ; Bing LI ; Xiujuan SUN ; Tiejun QIN ; Yue ZHANG ; Hongli ZHANG ; Liwei FANG ; Lijuan PAN ; Naibo HU ; Shiqiang QU ; Zhijian XIAO
Chinese Journal of Hematology 2016;37(1):26-29
OBJECTIVETo investigate the value of myeloproliferative neoplasms Symptom Assessment Form total symptom score (MPN-SAF-TSS)in assessing constitutional symptoms among Ph/BCR- ABL negative myeloproliferative neoplasm (MPN)patients.
METHODSA cohort of 628 MPN patients were evaluated by MPN- SAF- TSS.
RESULTSFatigue was the most common symptom (76.0%, 76.2%vs 89.9%)and the highest average severity of all the symptoms (3.46±2.97, 3.47±2.99vs 4.74±3.04 scores)among polycythemia vera (PV), essential thrombocythemia (ET)and primary myelofibrosis (PMF)patients. Using the MPN- SAF- TSS analysis, PMF patients showed highest burden of symptoms (28.9 ± 19.1), followed by PV patients (19.2 ± 16.8), and finally ET patients (17.1 ± 15.3). Instinct differences were observed between PMF and PV patients (χ(2)=6.371,P=0.021), PMF and ET patients (χ(2)= 14.020,P<0.001). No significant difference was found between PV and ET patients (χ(2)=2.281,P=0.191).
CONCLUSIONMPN- SAF- TSS was effective in evaluating the symptomatic burden among Ph/BCRABL negative MPN patients and could be used for serial assessment in this clinical setting.
Humans ; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative ; diagnosis ; physiopathology ; Polycythemia Vera ; complications ; Primary Myelofibrosis ; complications ; Thrombocythemia, Essential ; complications
6.Case of Bilateral Retinal Neovascularization Associated with Chronic Idiopathic Myelofibrosis.
Korean Journal of Ophthalmology 2010;24(2):131-133
We report a case of bilateral peripheral retinal neovascularization and chronic idiopathic myelofibrosis in a 69-year-old man. Ophthalmic examination revealed peripheral retinal nonperfusion with retinal neovascularization in both eyes and vitreous hemorrhage in the right eye. Fluorescein angiography of both eyes showed a marked midperipheral and peripheral avascular retina temporally with arteriovenous anastomosis and sea-fan neovascularizations. Blood tests showed pancytopenia and teardrop-shaped red blood cells, and bone marrow examination showed hypocellular marrow with severe fibrosis. The neovascularization was regressed following pars plana vitrectomy in the right eye and scatter laser photocoagulation in the left. The results suggest that peripheral retinal vessel occlusion and neovascularization may be associated with idiopathic myelofibrosis.
Aged
;
Chronic Disease
;
Fluorescein Angiography
;
Humans
;
Light Coagulation
;
Male
;
Primary Myelofibrosis/*complications
;
Retinal Neovascularization/*complications/therapy
;
Visual Acuity
;
Vitrectomy
;
Vitreous Hemorrhage/*complications/therapy
7.A Case of Post-Essential Thrombocythemia Myelofibrosis with Severe Osteosclerosis.
Kyo Kwan LEE ; Han Ik CHO ; Hyun Sook CHI ; Do Yeun KIM ; Seok Lae CHAE ; Hee Jin HUH
The Korean Journal of Laboratory Medicine 2010;30(2):122-125
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. After many years, a few patients with ET may develop bone marrow (BM) fibrosis and rarely develop osteosclerosis. A 60-yr-old female was admitted due to severe left upper quadrant abdominal discomfort. She had been diagnosed as ET 19 yrs ago. On liver computed tomography severe splenomegaly was shown. Laboratory tests revealed WBC 24.3x10(9)/L, hemoglobin 13.4 g/dL, platelets 432x10(9)/L, lactate dehydrogenase 4,065 IU/L (reference range; 240-480). Blood smear demonstrated leukoerythroblastosis, teardrop cells, and giant and hypogranular platelets. BM study revealed inadequate aspirate due to dry tap. BM biopsy showed clusters of dysplastic megakaryocytes, grade 3 fibrosis, and severe osteosclerosis. Major/minor BCR-ABL1 rearrangement and JAK2 V617F mutation were not detected. Cytogenetic studies revealed normal karyotype. According to the 2008 WHO diagnostic criteria, the patient was diagnosed as having post-essential thrombocythemia myelofibrosis with severe osteosclerosis.
Bone Marrow/pathology
;
Female
;
Humans
;
Megakaryocytes/pathology
;
Middle Aged
;
Osteosclerosis/complications/*diagnosis
;
Primary Myelofibrosis/complications/*diagnosis
;
Splenomegaly/etiology
;
Thrombocythemia, Essential/complications/*diagnosis
;
Tomography, X-Ray Computed
8.Analysis of clinical features and prognosis of primary myelodysplastic syndromes with myelofibrosis patients.
Tao SU ; Pei-hong ZHANG ; Ze-feng XU ; Hui-shu CHEN ; Tie-jun QIN ; Yue ZHANG ; Hong-li ZHANG ; Li-wei FAN ; Li-juan PAN ; Zhi-jian XIAO
Chinese Journal of Hematology 2012;33(5):378-382
OBJECTIVETo analyze the clinical features and prognosis of the primary myelodysplastic syndrome with myelofibrosis (MDS-MF) patients and to improve the cognition of MDS-MF.
METHODSFour hundred and sixty-six primary MDS patients with bone marrow (BM) biopsy were divided into two groups according to whether BM associated with fibrosis, the clinical features and prognosis of the two groups were analyzed retrospectively.
RESULTS167 (35.8%) MDS cases revealed myelofibrosis, of which MF-1 123 cases (26.4%), MF-2 40 cases (8.6%), MF-3 4 cases (0.9%). The proportion of hepatosplenomegaly in MDS-MF group was significantly higher than in MDS without MF group, the difference had statistical significance (P = 0.031). The proliferation of BM biopsy in MDS-MF group was significantly more active than in MDS without MF group. The number of blasts, megakaryocytes and abnormal megakaryocytes in MDS-MF group were significantly higher than in MDS without MF group, the differences had statistical significance (P < 0.05). Among the 345 patients who had available results of cytogenetic analysis, 121 cases were MDS-MF patients, the proportion of middle and high-risk prognostic group according to IPSS karyotype prognosis groups in MDS-MF group were significantly higher than in MDS without MF group, the differences had statistical significance (P = 0.047). The median survival was 17 (1 - 60) months in MDS-MF group, and was 32 (1 - 62) months in MDS without MF group. The difference had statistical significance (P = 0.001). Myelofibrosis had independent prognostic significance by multi-variable analysis (P = 0.019).
CONCLUSIONThe myelofibrosis in MDS is main the proliferation of reticular fiber. The proliferation of reticular fiber is closely related with the number of blast cells, the proliferation and developmental abnormalities of megakaryocytes and the karyotype. The prognosis of MDS-MF patients is poor.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Female ; Humans ; Karyotyping ; Male ; Middle Aged ; Myelodysplastic Syndromes ; complications ; diagnosis ; pathology ; Primary Myelofibrosis ; complications ; diagnosis ; pathology ; Prognosis ; Retrospective Studies ; Young Adult
9.Immunoglobulin D lambda multiple myeloma: a case report.
Shu-Kai QIAO ; Xue-Jun ZHANG ; Fu-Xu WANG ; Ling PAN ; Li YAO ; Zuo-Ren DONG
Journal of Experimental Hematology 2007;15(3):643-646
To improve the recognition of immunoglobulin D multiple myeloma and explore its clinical feature and laboratory examination characteristics, so as to reduce the the missed diagnosis and misdiagnosis, a case of IgD multiple myeloma (MM) with myelofibrosis and bone marrow necrosis is reported. The clinical feature, treatment and prognosis of IgDlambda MM were discussed. Immunoglobulin D multiple myeloma is a rare disease and predominantly occurs in young male patients, which shows an aggressive clinical course with poor response to conventional treatment and unfavorable prognosis. Immunoglobulin D multiple myeloma was usually misdiagnosed as a light chain type multiple myeloma by using routine laboratory examination. Immunoglobulin D monoclonal protein is not easy to be detected owing to its low protein level, resulting in missed diagnosis. Immunofixation electrophoresis is highly sensitive and specific for diagnosis of IgD MM, can enhance accuracy of diagnosis for this rare disease.
Adult
;
Diagnosis, Differential
;
Humans
;
Immunoglobulin D
;
blood
;
Immunoglobulin lambda-Chains
;
blood
;
Male
;
Multiple Myeloma
;
blood
;
complications
;
diagnosis
;
Primary Myelofibrosis
;
blood
;
complications
;
diagnosis
10.Pathological characteristics of leukemia patients with secondary myelofibrosis and their relationship with the prognosis of disease.
Jian-Hong GUAN ; Xiao-Ning WANG
Journal of Experimental Hematology 2013;21(2):311-314
The objective of this study was to investigate the pathological characteristics of leukemia patients with secondary myelofibrosis and their relationship with prognosis. The pathological characteristics of 29 leukemia patients with secondary myelofibrosis were observed, the degree of hyperplasia between bone marrow smear and biopsy, as well as the changes of myelofibrosis after treatment were compared, and their relationship with the prognosis was analysed. The results indicated that the myelofibrosis may cause the decrease of pseudoepitheliomatous in bone marrow smear, and the increase of reticulin could be observed except the primary pathological characteristics in the biopsy with Gomori staining ++ - +++, and the secondary myelofibrosis could be alleviated after treatment. The overall prognosis of these patients was poor. It is concluded that the bone marrow biopsy has the important diagnostic value for the leukemia patients with secondary myelofibrosis, and the myelofibrosis can be alleviated after treatment, but the overall prognosis of leukemia patients with secondary myelofibrosis is poor.
Adult
;
Aged
;
Bone Marrow
;
pathology
;
Female
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
complications
;
pathology
;
Male
;
Middle Aged
;
Primary Myelofibrosis
;
etiology
;
pathology
;
Young Adult